ID   LICR-HN5 R9.1
AC   CVCL_LI55
DR   Wikidata; Q54902514
RX   PubMed=26269754;
CC   Selected for resistance to: DrugBank; DB00002; Cetuximab (Erbitux).
CC   Derived from site: In situ; Oral cavity, tongue; UBERON=UBERON_0001723.
DI   NCIt; C4648; Tongue squamous cell carcinoma
DI   ORDO; Orphanet_457252; Squamous cell carcinoma of the oral tongue
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_8128 ! HN-5
SX   Male
AG   73Y
CA   Cancer cell line
DT   Created: 15-11-17; Last updated: 29-06-23; Version: 7
//
RX   PubMed=26269754;
RA   Boeckx C., Blockx L., Op de Beeck K., Limame R., Van Camp G.,
RA   Peeters M., Vermorken J.B., Specenier P., Wouters A., Baay M.,
RA   Lardon F.;
RT   "Establishment and characterization of cetuximab resistant head and
RT   neck squamous cell carcinoma cell lines: focus on the contribution of
RT   the AP-1 transcription factor.";
RL   Am. J. Cancer Res. 5:1921-1938(2015).
//